Humana (HUM) Stock Receives Price Target Hike at Cantor Fitzgerald

NEW YORK (TheStreet) -- Humana (HUM) stock received a price target increase to $230 from $160 by analysts at Cantor Fitzgerald. The firm reiterated its "buy" rating.

In Monday's early morning trading session, shares of Humana are dropping 0.48% to $213.62.

Analysts cited that the company is working with Goldman Sachs regarding a potential sale, according to a Dow Jones report on Friday. Potential bidders include Aetna (AET) and Cigna (CI), analysts noted.

"We are raising out price target to reflect the group's revaluation and HUM's position as the insurer most focused on Medicare Advantage," analysts added.

Regarding the Medicare Advantage members, Humana had 3.2 million members at 3/31/15, compared with 1.4 million for Anthem (ANTM) and 1.2 million for Aetna, the analyst note detailed.

Separately, TheStreet Ratings team rates HUMANA INC as a Buy with a ratings score of B+. TheStreet Ratings Team has this to say about their recommendation:

"We rate HUMANA INC (HUM) a BUY. This is driven by a few notable strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow."

If you liked this article you might like

Apple Is the Tom Brady of Stocks: Cramer's 'Mad Money' Recap (Thursday 8/31/17)

Boeing, Pure Storage, Activision Blizzard: 'Mad Money' Lightning Round

The Makings of Another Huge Rebound?

Healthcare Management Stocks Look Too Pricey for Activists

Tenet Dives After Worse Than Expected Quarter Leads to Lower 2017 Outlook